The pharmaceutical sector is currently undergoing a pivotal shift with the introduction of Aurigene.AI by Aurigene Pharmaceutical Services. This advanced platform stands at the forefront of drug discovery, potentially revolutionizing the way new medicines are developed. The integration of
For the biopharma industry, the start of the year holds one of the biggest events in the global industry calendar, JPM Week. It’s the ultimate meeting of minds, bringing together scientists, pharmaceutical industry professionals, bankers, investors, startup founders, journalists, and media. It sets
The biopharma industry is rapidly evolving and advancing in 2023. According to the Pharmaceutical Manufacturing Market Size report, its overall growth will continue at a rate of 11.34% from 2021 to 2028 . However, while the industry has long been labeled as recession-proof, organizations must stay
The recent COVID-19 pandemic undoubtedly reshaped healthcare systems around the world, while also increasing the pressure to develop and deliver better vaccines and treatments. Biopharmaceutical companies everywhere raced to find the first vaccine and the most effective drug as the healthcare
While the COVID-19 pandemic wreaked havoc and forced scientists and policymakers to create or search for vaccines and treatments, common disorders continued to affect millions of human lives. The pandemic made it harder for people suffering from chronic conditions to receive proper treatment in
The COVID-19 pandemic has demonstrated that it is essential for biopharmaceutical organizations to act quickly and become flexible in production. Experts, such as the CHEManager International team, view four factors as unsolved challenges. They claim that the first challenge is COVID-19 related.
With COVID-19 vaccines becoming more widely available around the world, and countries everywhere easing restrictions, a return to normal is now on everyone’s mind. While many activities are still recovering and regulations remain an important part of our daily lives, optimism is now rising for the f
